VANGUARD RESEARCH GROUP
Even though 2022 is a couple
of months old, we hope your
year is off to a great start and
want to wish all of you a
happy and healthy year.
COVID-19 has impacted all of
us in unprecedented ways. As
we continue to emerge from
this pandemic, we explore
new ways of conducting trials,
have new projects starting
and look forward to meeting
you face-to-face again at this
year’s NATCON in D.C.!
COVID-19 AND FUTURE CLINICAL CARE
The COVID-19 pandemic required the health industry to adjust
clinical care and research procedures quickly to adapt to the new
challenges. But some changes born out of that necessity are here to
stay, even after the pandemic is over. The articles below summarize
some major developments and their implications for our work going
VRG will staff a booth again at the National Council for Behavioral Health NATCON on April 11-12, 2022! Make sure to stop by VRG booth #312 to say hello and grab some goodies!
NEW STUDIES UPDATE
A STUDY INVOLVING AN FDA-APPROVED MEDICATION + DIGITAL APP FOR ADJUNCTIVE TREATMENT OF MDD.
A NOVEL PHARMACOLOGICAL TREATMENT FOR ACUTE AGITATION IN SCHIZOPHRENIA / BIPOLAR DISORDER FOR USE IN CRISIS STABILIZATION UNITS / PSYCH ER.
AN APP TRACKING HEALTH MEASURES TO ADIVSE CLINICAL CARE IN MOOD DISORDERS AND PSYCHOSIS.
TESTING A NEW THERAPY APP PROVIDING TREATMENT FOR MDD
If you are interested in learning more or participating, please email Marta Hauser at email@example.com.
FOLLOW US ON SOCIAL MEDIA